CDK9-IN-39 (1-7a-B1) is an orally active inhibitor of cyclin-dependent kinase 9 (CDK9), with an IC50 value of 6.51 nM. By inhibiting the phosphorylation of RNA polymerase II at the Ser2 site, CDK9-IN-39 induces cell (apoptosis) and can be used for colorectal cancer research.
Target:
Apoptosis|||CDK
* VAT and and shipping costs not included. Errors and price changes excepted
